Eli Lilly (LLY) is back in the spotlight after its investigational obesity drug retatrutide hit strong Phase 3 trial milestones, showing high and durable weight loss and sharpening investor focus on the company’s obesity franchise.

The recent retatrutide headlines and broader cardiometabolic data have come alongside firm share price momentum, with a 1 month share price return of 20.48% and a 1 year total shareholder return of 50.28%. The year to date share price is slightly lower, suggesting long term holders have seen strong compounding even as near term sentiment has been more mixed.

If obesity and cardiometabolic drugs are on your radar, it can also be worth scanning for other healthcare companies exposed to similar themes using our healthcare AI stock screener, where you can review 34 healthcare AI stocks

With Eli Lilly now worth about US$949.7b and trading around US$1,065 a share, yet screening on some models at roughly a 24% discount to intrinsic value, investors have to ask: is there still an opening here, or is the market already paying up for years of obesity and cardiometabolic growth?

Most Popular Narrative: 27.9% Undervalued

Against the last close of $1,065, the most followed fair value narrative sits materially higher at $1,477, framing Eli Lilly as significantly undervalued on that model.

Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet.

Want the full picture behind that premium fair value? The narrative leans on compounded growth, firm margins, and a valuation multiple more often associated with elite growth stories. Curious which assumptions really move the needle?

Result: Fair Value of $1,477.03 (UNDERVALUED)

However, the story can change quickly if retatrutide hits safety or adherence issues, or if obesity pricing pressure compresses margins faster than current models assume.

Next Steps

With sentiment clearly split between risks and rewards, this is a moment to move quickly: review the underlying data and decide where you stand using our 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Eli Lilly has sharpened your interest, do not stop here. Broaden your watchlist with other focused ideas that could sharpen how you think about risk and reward.

• Target income potential with stocks that currently offer higher yields and robust payout histories using our 10 dividend fortresses.
• Spot opportunities where quality and price still line up by scanning screener containing 21 high quality undiscovered gems before the crowd catches on.
• Prioritize resilience by filtering for companies that clear strict risk checks with the 69 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.